ARTICLE | Top Story

AstraZeneca, Isis team up on antisense delivery

November 14, 2014 2:23 AM UTC

AstraZeneca plc (LSE:AZN; NYSE:AZN) and Isis Pharmaceuticals Inc. (NASDAQ:ISIS) partnered to develop new targeted delivery methods for antisense oligonucleotides with a focus on cancer and cardiovascular and metabolic diseases. Each company will provide investigators and fund its own research contributions; the companies will share rights to the results.

Neither company would discuss whether the deal includes other financial terms. ...